JAK2, Active
Recombinant human JAK2 (804-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Catalog No. J02-11G
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| J02-11G-05 | 5 ug | $226 | |
| J02-11G-10 | 10 ug | $325 | |
| J02-11G-BULK | BULK | Contact Us |
Recombinant human JAK2 (804-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Catalog No. J02-11G
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| J02-11G-05 | 5 ug | $226 | |
| J02-11G-10 | 10 ug | $325 | |
| J02-11G-BULK | BULK | Contact Us |
Overview:
JAK2 is a member of intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway (1). JAK2 has two near-identical phosphate-transferring domains. One domain exhibits the kinase activity while the other stabilizes the JAK conformational structure. JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin. JAK2 has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon (2).
Gene Aliases:
none
Genbank Number:
References:
1. Lacronique, V. Et al : A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science, 1997; 278: 1309-1312.
2. Ho, J.M. et al: TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood, 2002; 100: 1438-1448.
Specific Activity:
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
|
Purity:
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
|
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Molecular Weight:
~63 kDa
RESTRICTION:
All orders for customers in the USA must be placed directly through SignalChem (This product cannot be purchased through Distributors in the USA). This product shall not be used to commercially screen drug molecules being developed as JAK1 or JAK2 inhibitors nor for any in vitro diagnostic purposes. Any such activity will be outside the scope of the research use only label license. The product is protected by the following patents: US5,910,426; US5,852,184; US5,821,069; US5,716,818,US5,658,791.
Huang Yongqi et al., The Activity and Stability of the Intrinsically Disordered Cip/Kip Protein Family AreRegulated by Non-Receptor Tyrosine Kinases Journal of Molecular Biology January 2015 10.1016/j.jmb.2014.11.011
Zhang Jing et al., Dehydrocrenatidine is a Novel JAK Inhibitor Molecular Pharmacology January 2015 10.1124/mol.114.095208
Deng Yang et al., Global Analysis of Human Nonreceptor Tyrosine Kinase Specificity Using High-Density Peptide Microarrays Journal of Proteome Research August 2014 10.1021/pr500503q
JW Singer et al., Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. Journal of Experimental Pharmacology August 2016 10.2147/JEP.S110702
Kesarwani Meenu et al., Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance Science Reports September 2015 10.1038/srep14538
et al., Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability Disease Models & Mechanisms November 2021
Cancer, Cardiovascular Disease, Cytoplasmic Tyrosine Kinases, Inflammation, JAK/STAT Pathway
STAY CONNECTED
Fax: 1-604-232-4601
Toll Free: 1-866-954-6273
info@signalchem.com